Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Zomedica Pharmaceuticals Corp
(NY:
ZOM
)
0.1330
+0.0029 (+2.23%)
Official Closing Price
Updated: 8:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Zomedica Pharmaceuticals Corp
< Previous
1
2
3
4
Next >
Zomedica to Present at the Noble Capital Markets Virtual Healthcare Conference on April 17, 2024
April 09, 2024
Via
ACCESSWIRE
Zomedica Reports Record Revenue of $7.3 Million for the Fourth Quarter and $25.2 Million for the Full Year 2023, Reflecting 33% Annual Growth; 69% Gross Margin and $100.5 Million in Liquidity
April 01, 2024
Via
ACCESSWIRE
Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET
March 20, 2024
Via
ACCESSWIRE
Zomedica Announces Publication of Research Concluding TRUFORMA(R) Platform is More Accurate Diagnostic Test for Feline Hyperthyroidism than Chemiluminescent Immunoassay (CLIA) Platform
March 14, 2024
Via
ACCESSWIRE
Zomedica Provides NYSE American Listing Update
March 13, 2024
Via
ACCESSWIRE
Zomedica Announces Sponsorship of Educational Presentations at Fetch dvm360 Veterinary Conferences
March 12, 2024
Via
ACCESSWIRE
Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs
March 07, 2024
Via
ACCESSWIRE
Zomedica to Present at the Sidoti Small Cap Conference March 14, 2024
March 05, 2024
Via
ACCESSWIRE
Zomedica Announces Sponsorship of Educational Presentations at Major Veterinary Health Conferences
February 08, 2024
Via
ACCESSWIRE
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Zomedica Shareholders Vote for the Share Consolidation (Reverse Stock Split)
February 06, 2024
Via
ACCESSWIRE
Zomedica to Host Virtual Investor Day February 13 at 3:00 p.m. ET
February 06, 2024
Via
ACCESSWIRE
Open Letter to Zomedica Shareholders from your Chief Executive Officer
January 31, 2024
Via
ACCESSWIRE
Zomedica to Participate in the Lytham Partners 2024 Investor Select Conference
January 30, 2024
Via
ACCESSWIRE
Leading Proxy Advisory Firm ISS Recommends Zomedica Shareholders Vote "FOR" Proposed Reverse Stock Split
January 25, 2024
Via
ACCESSWIRE
Zomedica Announces Preliminary 2023 Revenue; Provides Revenue Guidance for 2024, and Rationale for Share Consolidation ("Reverse Stock Split")
January 17, 2024
Via
ACCESSWIRE
Zomedica Corp. to Host Conference Call on January 17, 2024, at 4:30 p.m. ET to Provide a Business Update, Preliminary 2023 Revenue and Cash Position, and Discuss the Proposed Reverse Stock Split; Provides Notice of Special Virtual-Only Meeting of
January 10, 2024
Via
ACCESSWIRE
Zomedica Announces Publication of Research Validating Better Patient Acceptance of PulseVet(R) Electro-hydraulic Shock Wave Therapy without Sedation Utilizing Novel “X-Trode” Handpiece
January 04, 2024
Via
ACCESSWIRE
Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease
December 18, 2023
Via
ACCESSWIRE
Zomedica Announces Presentation of Clinical Data in Support of New Indications for PulseVet Shock Wave Therapy at Annual Meeting of American Association of Equine Practitioners
December 06, 2023
Via
ACCESSWIRE
Zomedica to Present at Noble Capital Markets' 19th Annual Emerging Growth Equity Conference
November 28, 2023
Via
ACCESSWIRE
Zomedica to Present at the 35th Annual Piper Sandler Healthcare Conference
November 20, 2023
Via
ACCESSWIRE
Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies
November 13, 2023
Via
ACCESSWIRE
Zomedica to Report Third Quarter 2023 Financial Results and Provide Business Update on November 13 at 4:30 p.m. ET
November 02, 2023
Via
ACCESSWIRE
Zomedica to Participate in the Lytham Partners Fall 2023 Investor Conference
October 10, 2023
Via
ACCESSWIRE
Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech LLC, Accelerating Timeline to Gain Control of Manufacturing and Research & Development
October 05, 2023
Via
ACCESSWIRE
Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of First-and-only Point of Care eACTH Assay for Diagnosis and Management of Cushing’s Disease in Horses
September 14, 2023
Via
ACCESSWIRE
Zomedica Provides Corporate Update
September 13, 2023
Via
ACCESSWIRE
Zomedica Closes Acquisition of Structured Monitoring Products Adding Revolutionary VetGuardian Touchless Vital Signs Monitor to Product Portfolio
September 05, 2023
Via
ACCESSWIRE
Zomedica to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 31, 2023
Via
ACCESSWIRE
Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity
August 10, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.